Medibio Ltd
ASX:MEB

Watchlist Manager
Medibio Ltd Logo
Medibio Ltd
ASX:MEB
Watchlist
Price: 0.02 AUD Market Closed
Market Cap: 122m AUD
Have any thoughts about
Medibio Ltd?
Write Note

Medibio Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Medibio Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Medibio Ltd
ASX:MEB
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mach7 Technologies Ltd
ASX:M7T
Accounts Receivables
AU$6m
CAGR 3-Years
4%
CAGR 5-Years
12%
CAGR 10-Years
90%
4DMedical Ltd
ASX:4DX
Accounts Receivables
AU$1.1m
CAGR 3-Years
36%
CAGR 5-Years
25%
CAGR 10-Years
N/A
CogState Ltd
ASX:CGS
Accounts Receivables
$10m
CAGR 3-Years
8%
CAGR 5-Years
18%
CAGR 10-Years
14%
Pro Medicus Ltd
ASX:PME
Accounts Receivables
AU$49.1m
CAGR 3-Years
27%
CAGR 5-Years
21%
CAGR 10-Years
34%
Medadvisor Ltd
ASX:MDR
Accounts Receivables
AU$13m
CAGR 3-Years
6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Medibio Ltd
Glance View

Market Cap
122m AUD
Industry
Health Care

Medibio Ltd. engages in the clinical research, product development and early stage commercialization of a mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. The firm offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company offers a software called MEBsleep, a medical device that analyses Electroencephalogram (EEG) and Electrocardiogram (ECG) data collected during polysomnography to verify sleep stages and heart rate variability (HRV) in patients suffering from primary or secondary sleep disturbances. The Company’s subsidiaries include Bioprospect Australia Pty Ltd, Australian Phytochemicals Pty Ltd, BioProspect America Pty Ltd, Medibio Limited USA, Invatec Health Pty Ltd and Annapanna Pty Ltd.

MEB Intrinsic Value
0.001 AUD
Overvaluation 97%
Intrinsic Value
Price

See Also

Back to Top